Status:
UNKNOWN
Feasibility and Safety of Combining Anti-malarial With Deworming Drugs in African Children
Lead Sponsor:
London School of Hygiene and Tropical Medicine
Collaborating Sponsors:
Université de Thies, UFR Santé, Senegal
Conditions:
Malaria
Soil Transmitted Helminths
Eligibility:
All Genders
1-14 years
Phase:
NA
Brief Summary
Malaria remains a major health problem, especially in sub-Saharan Africa where more than 90% of the disease and deaths occur in children. Adding to this high burden among the children is the co-existe...
Eligibility Criteria
Inclusion
- Male and female children aged 1-14 years;
- Provision of a written informed consent by the parent/caregiver and a positive assent by children aged ≥ 12 years (in line with legal regulations in Senegal);
- Willingness to provide finger-prick blood samples, urine, and stool samples;
- Residence in the study area for at least six months
Exclusion
- Acutely ill child at the time of the drug administration;
- Child whose parents/caregivers decline to provide consent;
- A known HIV positive child receiving cotrimoxazole prophylaxis;
- A child who has received a dose of any of sulphadoxine-pyrimethamine, amodiaquine, albendazole or praziquantel during the previous six months;
- A child with a known allergy to any of sulphadoxine-pyrimethamine, amodiaquine, albendazole or praziquantel.
Key Trial Info
Start Date :
June 16 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2023
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT05354258
Start Date
June 16 2022
End Date
September 1 2023
Last Update
July 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Saraya Health Centre
Saraya, Région de Kédougou, Senegal, 00221